InfectionCommon DDxICD-10 L03.x

Cellulitis

Bacterial cellulitis ยท acute bacterial skin and skin-structure infection (ABSSSI)

Cellulitis is an acute bacterial infection of the dermis and subcutaneous tissue, most commonly due to ฮฒ-haemolytic streptococci and Staphylococcus aureus. In skin-oncology practice it is a daily differential for inflamed epidermoid cysts, post-operative infection, lymphoedematous limb flares, panniculitis and lobular angiosarcoma. The CREST/Eron classification and NICE NG141 framework guide oral vs IV management and admission decisions.

CurrentLast reviewed 16 May 2026
Clinical image of Cellulitis
Cellulitis. Image sourced from DermNet New Zealand. Used under CC BY-NC-ND 4.0. No endorsement implied.

Microbiology

  • ฮฒ-haemolytic streptococci (group A, C, G) โ€” most common; predominate in classic erysipelas-like cellulitis and recurrent disease.
  • Staphylococcus aureus โ€” particularly with abscess / purulent component; MRSA in care-home or healthcare-associated settings.
  • Atypical / contact-exposure organisms:
    • Vibrio vulnificus, Aeromonas hydrophila โ€” fresh / salt water exposure.
    • Pasteurella multocida, Capnocytophaga canimorsus โ€” animal bites.
    • Eikenella corrodens โ€” human bites.
    • Erysipelothrix rhusiopathiae โ€” fish / meat handlers (erysipeloid).
    • Mycobacterium marinum โ€” fish-tank / aquarium granuloma.

Clinical features and assessment

  • Acute, hot, tender, poorly-defined erythema with rapid expansion; commonly unilateral; lower limb most frequent in adults.
  • Systemic features (fever, rigors, leucocytosis) in classes II-IV.
  • Mark the edge at presentation to monitor progression.
  • Eron / CREST classification:
    • I โ€” no systemic toxicity or comorbidity โ†’ oral antibiotics outpatient.
    • II โ€” systemic features or significant comorbidity โ†’ home IV via OPAT or short admission.
    • III โ€” systemic toxicity (SIRS), unstable comorbidity, limb-threatening โ†’ admission, IV antibiotics.
    • IV โ€” sepsis, necrotising fasciitis suspected โ†’ emergency surgical review.

Skin-oncology differentials

  • Lymphoedema flare / acute on chronic โ€” common after lymphadenectomy.
  • Inflamed epidermoid / sebaceous cyst โ€” well-defined; central punctum; rubbery on resolution.
  • Erysipelas โ€” sharply demarcated, raised, classically facial / lower-limb (separate page).
  • Acute contact dermatitis โ€” pruritus dominates over pain; geometric distribution.
  • Stasis dermatitis / lipodermatosclerosis โ€” chronic, bilateral, hyperpigmented; not erysipelas-like.
  • Deep vein thrombosis โ€” calf tenderness, Homans sign; Wells score; D-dimer.
  • Inflammatory breast cancer or recurrent cutaneous metastasis โ€” peau d'orange; firm.
  • Cutaneous angiosarcoma โ€” particularly in older adults, post-mastectomy lymphoedema (Stewart-Treves) or after radiotherapy.
  • Necrotising fasciitis โ€” pain out of proportion, dusky / bullous skin, crepitus, systemic toxicity โ€” surgical emergency.
  • Inflammatory carcinoma erysipeloides โ€” breast / gastric / lung metastasis simulating cellulitis.

Investigations

  • Routine: FBC, CRP, U&E, LFT, lactate, blood cultures if class II+.
  • Swab any open wound or pustule; aspirate fluctuant collections.
  • Imaging: lower-limb venous Doppler if DVT possible; soft-tissue ultrasound for collection; MRI / CT if necrotising fasciitis or bone involvement suspected.
  • If recurrent: consider tinea pedis as portal of entry; assess for chronic lymphoedema, obesity, varicose eczema.
  • If unilateral, painless, slowly progressive in older adult โ€” biopsy to exclude carcinoma erysipeloides or angiosarcoma.

Management

  • NICE NG141 (2019):
    • Class I (no MRSA risk): oral flucloxacillin 500 mg-1 g QDS for 5-7 days (or clarithromycin / doxycycline if penicillin-allergic).
    • Facial cellulitis: co-amoxiclav 500/125 mg TDS.
    • Class II-III: IV co-amoxiclav 1.2 g TDS or ceftriaxone 1-2 g OD; consider OPAT.
    • MRSA risk: vancomycin / teicoplanin / linezolid per local protocol.
    • Animal bite: co-amoxiclav.
  • Address portal of entry (interdigital tinea, fissures, eczema).
  • Limb elevation, analgesia, hydration; mark erythema edge daily.
  • Recurrence prophylaxis: penicillin V 250 mg BD long-term for โ‰ฅ2 episodes in 12 months in same area (PATCH trials).

References

  1. NICE NG141. Cellulitis and erysipelas: antimicrobial prescribing. London: NICE; 2019 (last reviewed 2024).
  2. Eron LJ et al. Managing skin and soft tissue infections: expert panel recommendations on key decision points. J Antimicrob Chemother. 2003;52(Suppl 1):i3-17.
  3. CREST. Guidelines on the management of cellulitis in adults. Belfast: CREST; 2005.
  4. Thomas KS et al. Penicillin to prevent recurrent leg cellulitis (PATCH II trial). N Engl J Med. 2013;368:1695-1703.
  5. Stevens DL et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections. Clin Infect Dis. 2014;59:e10-e52.

Spot a correction?

If any clinical statement, citation or link on this page needs updating, please email admin@skinoncology.net with the page name, the proposed correction and the supporting source.